June 21-24, 2021 | 9:00AM EDT | 1:00PM UTC | 3:00PM CEST*
*Program is in development and subject to change
The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.
Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.
The discovery of genomic and epigenetic alterations in individual cancers has led to a plethora of precision medicine innovations and therapeutic successes in oncology. Accordingly, cancer treatments have migrated away from the “one size fits all” approach. However, even as precision medicine is becoming more multi-disciplinary, progress is still hindered by insufficient collaboration between basic researchers, drug development programs, and physician scientists with broad expertise across cancer biology, genomics and other relevant fields.
Therefore, this conference will bring together diverse experts from academic, pharma/biotech, medical and government sectors to discuss current challenges and future directions in precision oncology. In particular, the meeting will foster crosstalk between clinicians, cancer biologists and genomic scientists to identify and address key knowledge gaps that limit the advancement of new precision therapies. This conference program will cover topics such as novel genomic insights, therapeutically promising mechanisms and cancer drug targets, recent translational breakthroughs, and the incorporation of new diagnostic tools as companions to new precision treatments.
The program will emphasize leading-edge advances in “reverse translation” technologies, such as liquid biopsies and single cell genomics, in addition to innovative, first-in-class approaches to novel therapeutics. Ultimately, the goal of the conference is to forge new collaborations across scientific and clinical boundaries, to advance the next generation of precision medicines against cancer.
Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD
‣ For Short Talk Consideration: May 10, 2021
‣ For Poster Booth: June 7, 2021
ePoster / SciTalk Submission: June 10, 2021
Financial Aid Application: June 7, 2021
*Abstract submission is required in order to submit an ePoster and/or Scitalk
Graduate students and postdoctoral fellows, as well as individuals from low- and middle- income countries (all career stages) working in science and medicine related fields, are eligible to apply for a FREE registration code.
Find out more about financial aid opportunities here!
Showcase your work to global audiences on the eSymposia platform!
Submit your abstract for the opportunity to be selected for a short talk presentation alongside field leaders on the meeting program! See Abstract Deadline for Short Talk Consideration
ePoster presenters will be provided with their own dedicated page on the event website to display their work in multiple formats and interact with meeting participants. ePoster features include:
To submit your work for an ePoster presentation, and to be considered for short talk selection, go to the “Submit an Abstract” tab on the event homepage.
ETH Zürich, Switzerland
Johns Hopkins University School of Medicine, USA
University of Torino, Italy
Jaclyn A. Biegel
Children's Hospital Los Angeles and Keck School of Medicine of USC, USA
Jason S. Carroll
Cancer Research UK, University of Cambridge, UK
ORIC Pharmaceuticals, USA
Todd R. Golub
Broad Institute, USA
Foundation Medicine, USA
John V. Heymach
University of Texas MD Anderson Cancer Center, USA
Klaus P. Hoeflich
Blueprint Medicines, USA
Russell W. Jenkins
Massachusetts General Hospital, USA
Dana-Farber Cancer Institute, Harvard Medical School, USA
Yale School of Medicine, USA
Scott W. Lowe
Memorial Sloan Kettering Cancer Center, USA
Elaine R. Mardis
Nationwide Children's Hospital, USA
Memorial Sloan Kettering Cancer Center, USA
Memorial Sloan-Kettering Cancer Center, USA
Alice T. Shaw
Massachusetts General Hospital Cancer Center, USA
Gromoslaw A. Smolen
Celsius Therapeutics, USA
NCI, National Institutes of Health, USA
Cold Spring Harbor Laboratory, USA
University of California, Berkeley, USA
Funding for this conference was made possible (in part) by Grant No. [GRANT NUMBER - UPDATE] from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.
This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.